IDIX---I'm certain the shareholders are breathing a sigh of relief along with IDIX's management. Without NVS's help the company would have been forced to raise capital by further dilution at much lower prices due to the market's reaction on NVS walking away from the drug candidate.
Not a bad deal at all, both company's will co-promote in the US and Europe, and NVS pays for the clinical trials. Lovely, isn't it nice when someone else pays for your pivotals!!!
News 
Market Data 
Discover 
